Mizuho Securities Keeps Their Buy Rating on BridgeBio Pharma (BBIO)

By Austin Angelo

In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on BridgeBio Pharma (BBIOResearch Report), with a price target of $51.00. The company’s shares closed last Monday at $36.14.

According to TipRanks.com, Syed has 0 stars on 0-5 star ranking scale with an average return of -6.7% and a 48.1% success rate. Syed covers the Healthcare sector, focusing on stocks such as Atara Biotherapeutics, Coherus Biosciences, and Wave Life Sciences.

BridgeBio Pharma has an analyst consensus of Strong Buy, with a price target consensus of $44.00.

See today’s analyst top recommended stocks >>

Based on BridgeBio Pharma’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $59.98 million. In comparison, last year the company had a GAAP net loss of $31.4 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 development programs includes product candidates from early discovery to late-stage development.